12-Jun-2026
Globe Newswire (Thu, 11-Jun 8:00 PM ET)
Hutchmed Moves HMPL-760 Forward With Food-Effect Study, Signaling Steady Pipeline Progress
TipRanks (Thu, 11-Jun 12:31 PM ET)
HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting
Globe Newswire (Thu, 21-May 8:00 PM ET)
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
Globe Newswire (Wed, 29-Apr 8:44 AM ET)
Globe Newswire (Wed, 29-Apr 6:00 AM ET)
Globe Newswire (Thu, 23-Apr 8:35 AM ET)
HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026
Globe Newswire (Wed, 8-Apr 8:00 PM ET)
Globe Newswire (Sun, 22-Mar 8:00 PM ET)
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
Hutchmed (China) Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol HCM.
As of June 12, 2026, HCM stock price climbed to $10.96 with 27,145 million shares trading.
HCM has a beta of 1.11, meaning it tends to be more sensitive to market movements. HCM has a correlation of 0.09 to the broad based SPY ETF.
HCM has a market cap of $1.88 billion. This is considered a Small Cap stock.
Last quarter Hutchmed (China) Limited - American Depositary Shares reported $549 million in Revenue and $2.62 earnings per share. This fell short of revenue expectation by $-43 million and exceeded earnings estimates by $1.19.
In the last 3 years, HCM traded as high as $21.92 and as low as $10.40.
The top ETF exchange traded funds that HCM belongs to (by Net Assets): SPDW, DFEM, NSI, DFAX, DFSE.
HCM has underperformed the market in the last year with a price return of -38.1% while the SPY ETF gained +24.1%. HCM has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -22.8% and -4.3%, respectively, while the SPY returned +11.6% and -1.9%, respectively.
HCM support price is $10.43 and resistance is $10.93 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HCM shares will trade within this expected range on the day.